Overview

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2023-06-26

Target enrollment:

Participant gender:

Summary

To compare the therapeutic effect of vinorelbine used alone or combined with apatinib mesylate for recurrent or metastatic TNBC patients who have at least received one chemotherapy regimen, including anthracyclines and taxanes, providing clinical evidence for multi-line treatment options for advanced TNBC.

Phase:

Phase 2

Details

Lead Sponsor:

Liaoning Tumor Hospital & Institute

Treatments:

Apatinib
Vinorelbine